Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs

J. Bohn, C. Kortepeter, M. Muñoz, K. Simms, S. Montenegro, G. Dal Pan

Research output: Contribution to journalArticle

Abstract

Spontaneous adverse event reports constitute an important source of information on previously unknown adverse reactions to marketed medicines. However, the dynamics of such reporting following generic introduction are poorly understood. Using adverse event reports on five antiepileptic drugs from the US Food and Drug Administration's Adverse Event Reporting System, we describe temporal trends in adverse event reporting before and after generic introduction, and survey the quality of product-identifying information contained therein. The majority of reports were sent by innovator drug manufacturers while few were sent by generic manufacturers, even when generics accounted for >90% of dispensed prescriptions. We manually reviewed narratives from 2,500 reports and found that the suspect product type (brand or generic) could not be determined in 84% of reports, while generic products (16%) were identified more often than brand-name products (

Original languageEnglish (US)
Pages (from-to)508-517
Number of pages10
JournalClinical Pharmacology and Therapeutics
Volume97
Issue number5
DOIs
StatePublished - May 1 2015
Externally publishedYes

Fingerprint

Generic Drugs
Drug-Related Side Effects and Adverse Reactions
Anticonvulsants
Names
Prescriptions
Food
Pharmaceutical Preparations
Surveys and Questionnaires

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs. / Bohn, J.; Kortepeter, C.; Muñoz, M.; Simms, K.; Montenegro, S.; Dal Pan, G.

In: Clinical Pharmacology and Therapeutics, Vol. 97, No. 5, 01.05.2015, p. 508-517.

Research output: Contribution to journalArticle

Bohn, J, Kortepeter, C, Muñoz, M, Simms, K, Montenegro, S & Dal Pan, G 2015, 'Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs', Clinical Pharmacology and Therapeutics, vol. 97, no. 5, pp. 508-517. https://doi.org/10.1002/cpt.81
Bohn, J. ; Kortepeter, C. ; Muñoz, M. ; Simms, K. ; Montenegro, S. ; Dal Pan, G. / Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs. In: Clinical Pharmacology and Therapeutics. 2015 ; Vol. 97, No. 5. pp. 508-517.
@article{949ed72da1ac492793262519662584e2,
title = "Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs",
abstract = "Spontaneous adverse event reports constitute an important source of information on previously unknown adverse reactions to marketed medicines. However, the dynamics of such reporting following generic introduction are poorly understood. Using adverse event reports on five antiepileptic drugs from the US Food and Drug Administration's Adverse Event Reporting System, we describe temporal trends in adverse event reporting before and after generic introduction, and survey the quality of product-identifying information contained therein. The majority of reports were sent by innovator drug manufacturers while few were sent by generic manufacturers, even when generics accounted for >90{\%} of dispensed prescriptions. We manually reviewed narratives from 2,500 reports and found that the suspect product type (brand or generic) could not be determined in 84{\%} of reports, while generic products (16{\%}) were identified more often than brand-name products (",
author = "J. Bohn and C. Kortepeter and M. Mu{\~n}oz and K. Simms and S. Montenegro and {Dal Pan}, G.",
year = "2015",
month = "5",
day = "1",
doi = "10.1002/cpt.81",
language = "English (US)",
volume = "97",
pages = "508--517",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs

AU - Bohn, J.

AU - Kortepeter, C.

AU - Muñoz, M.

AU - Simms, K.

AU - Montenegro, S.

AU - Dal Pan, G.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Spontaneous adverse event reports constitute an important source of information on previously unknown adverse reactions to marketed medicines. However, the dynamics of such reporting following generic introduction are poorly understood. Using adverse event reports on five antiepileptic drugs from the US Food and Drug Administration's Adverse Event Reporting System, we describe temporal trends in adverse event reporting before and after generic introduction, and survey the quality of product-identifying information contained therein. The majority of reports were sent by innovator drug manufacturers while few were sent by generic manufacturers, even when generics accounted for >90% of dispensed prescriptions. We manually reviewed narratives from 2,500 reports and found that the suspect product type (brand or generic) could not be determined in 84% of reports, while generic products (16%) were identified more often than brand-name products (

AB - Spontaneous adverse event reports constitute an important source of information on previously unknown adverse reactions to marketed medicines. However, the dynamics of such reporting following generic introduction are poorly understood. Using adverse event reports on five antiepileptic drugs from the US Food and Drug Administration's Adverse Event Reporting System, we describe temporal trends in adverse event reporting before and after generic introduction, and survey the quality of product-identifying information contained therein. The majority of reports were sent by innovator drug manufacturers while few were sent by generic manufacturers, even when generics accounted for >90% of dispensed prescriptions. We manually reviewed narratives from 2,500 reports and found that the suspect product type (brand or generic) could not be determined in 84% of reports, while generic products (16%) were identified more often than brand-name products (

UR - http://www.scopus.com/inward/record.url?scp=84932123603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932123603&partnerID=8YFLogxK

U2 - 10.1002/cpt.81

DO - 10.1002/cpt.81

M3 - Article

C2 - 25670505

AN - SCOPUS:84932123603

VL - 97

SP - 508

EP - 517

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -